Researchers Support Global NCD Push.
Researchers from the Center for Global Health and Development will evaluate a partnership of more than 20 biopharmaceutical companies to improve non-communicable disease (NCD) care in low- and lower-middle-income countries around the world.
Access Accelerated launched at the World Economic Forum in Davos, Switzerland, on January 18. The first-of-its-kind global initiative is a partnership between the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the World Bank, and the Union for International Cancer Control (UICC).
Over the next three years, SPH researchers will help monitor progress, measure achievements, and identify opportunities to improve programs that promote access to NCD care and prevention. They will develop the first common framework for measuring and evaluating NCD prevention and care programs and support new, standardized measurements across those programs.
“This is a great opportunity for pharmaceutical company initiatives to be evaluated and receive credit when positive outcomes are shown,” says Professor of Global Health Richard Laing, the evaluation project’s principal investigator.
“I am particularly excited by the commitment to transparent and robust evaluation methods that the companies have agreed to in this initiative” says Assistant Professor of Global Health Peter Rockers, the other principal investigator on the Access Accelerated evaluation.
All aspects of the initiative will be transparent and placed in the public domain.
The co-investigators are Associate Professor of Global Health Veronika Wirtz, Associate Professor of Global Health Taryn Vian, Assistant Professor of Global Health Nancy Scott, and Clinical Assistant Professor of Global Health Warren Kaplan.